Product Code: RP-ID-10070747 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10070747
Market Overview:
Gaucher Disease Treatment Market Segmentation by Disease Type {Type 1 (Neuropathic Form), Type 2 (Perinatal Lethal Form), and Type 3 (Slow-Neurologic Decay Form)}; by Treatment Type {Enzyme Replacement Therapy (ERT), and Substrate Reduction Therapy (SRT)}; and by Application (Hospitals, Ambulatory Surgical Centers, and Clinical Research Institutes)-Global Demand Analysis & Opportunity Outlook 2031
Global Gaucher Disease Treatment Market Highlights Over 2022 - 2031
The global Gaucher disease treatment market garnered an approximate revenue of USD 1.9 billion in the year 2021 and is estimated to grow at a CAGR of ~5% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to growing incidences of Gaucher disease globally, along with the rising need for suitable and precise treatment for the disease. For instance, the prevalence of Gaucher disease worldwide is known to be between 0.70 and 1.70 per 1 million individuals. Moreover, the development and launching of novel drugs for treatment is another major factor estimated to influence the market growth. Additionally, support initiatives by government to spread awareness about the treatment for the disease is also expected to boost the market growth in the coming years.
CLICK TO DOWNLOAD A SAMPLE REPORT
Gaucher disease is a genetic or hereditary condition in which body fat (lipid) called glucosylceramide accumulates in tissue and organs, primarily due to a defect in the enzyme B-glucocerebrosidase. This accumulation leads to various consequences such as low blood platelet count, exhaustion, and bruising. Enlargement of the liver and spleen are additional symptoms of Gaucher disease. People suffering with Gaucher disease may or may not show any symptom at times while youngsters are more susceptible to the condition than adults.
The global Gaucher disease treatment market is segmented on the basis of disease type, treatment type, and application. The disease type segment is further divided into type 1 (neuropathic form), type 2 (perinatal lethal form), and type 3 (slow-neurologic decay form). Among these, the type 1 disease segment is estimated to hold the largest market size by growing at a significant CAGR over the forecast period. the common symptoms of type 1 disease include spleen and liver enlargement, bone problems, and fatigue. The growth of the segment can be associated with the rising number of people suffering from type 1 disease across the globe. As per the National Gaucher Foundation, approximately 95 percent of total cases are affected by type 1 Gaucher disease.
Global Gaucher Disease Treatment Market Regional Synopsis
Regionally, the global Gaucher disease treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the North America region witnessed significant growth in the year 2021 on the back of advancements in research and development for rare disorders. Moreover, development in the healthcare sector as well as rising awareness among people about the treatment are expected to drive market growth. For instance, in the United States, nearly 6,000 people were known to be affected by the disease. Alternatively, the market in the Asia Pacific is anticipated to witness generous modest growth by growing at a higher CAGR over the forecast period. The growth of the market can primarily be associated with the growing prevalence of Gaucher disease in the region. The constant development in healthcare infrastructure and support initiatives taken by the government to spread awareness among people about the treat are estimated to boost the market growth.
Market Segmentation
Our in-depth analysis of the global Gaucher disease treatment market includes the following segments:
By Disease Type
-
Type 1 (Neuropathic Form)
-
Type 2 (Perinatal Lethal Form)
-
Type 3 (Slow-neurologic Decay Form)
By Treatment Type
-
Enzyme Replacement Therapy (ERT)
-
Substrate Reduction Therapy (SRT)
By Application
-
Hospitals
-
Ambulatory Surgical Centers
-
Clinical Research Institutes
Growth Drivers and Challenges Impacting the Growth of the Global Gaucher Disease Treatment Market
Growth Drivers
-
Growing cases of Gaucher disease
-
Extensive research and development in the field
-
Increasing support initiatives by the government
Challenges
-
High cost of treatment
-
Lack of clinical trial for approval of drugs
Key Companies Dominating the Global Gaucher Disease Treatment Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global Gaucher disease treatment market that are included in our report are AVROBIO, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer Inc., PerkinElmer Inc., GlaxoSmithKline plc, AstraZeneca PLC, Sanofi-aventis Groupe, Takeda Pharmaceutical Company Limited, and Janssen Global Services, LLC among others.
Latest Developments in the Global Gaucher Disease Treatment Market:
-
14 January 2020: AVROBIO, Inc. announced that it has received a clearance notice for its investigational gene therapy for Gaucher disease treatment, AVR-RD-02, by the U.S Food and Drug Administration (FDA).
-
15 December 2020: Eli Lilly and Company announced the acquisition of Prevail Therapeutics in order to establish a gene therapy program to treat fatal genetic diseases.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- AVROBIOInc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Pfizer Inc.
- PerkinElmer Inc.
- GlaxoSmithKline plc
- AstraZeneca PLC
- Sanofi-aventis Groupe
- Takeda Pharmaceutical Company Limited
- Janssen Global Services
- LLC
Related Reports
Proof of Quality & Reliability
